Therapy News and Research

RSS

Patients with episodic gallbladder pain may benefit from cholecystectomy

According to a new study in Clinical Gastroenterology and Hepatology, better understanding of a patient's abdominal pain could help physicians know which patients will benefit most from surgical removal of the gallbladder.

14 Oct 2011

InnaVirVax announces Phase I/IIa clinical trial authorization for its VAC-3S HIV vaccine

InnaVirVax, a biopharmaceutical company dedicated to the development of therapeutic and diagnostic solutions in pathologies associated with immune dysregulation, declared today that it has obtained authorization from the French drug agency (AFSSAPS) to start a Phase I/IIa clinical study of its therapeutic vaccine VAC-3S for the treatment of HIV infections. This authorization intervenes only two years and half after the launching of InnaVirVax’s activities.

14 Oct 2011

Top-line results from POZEN's PA32540 Phase 3 trial on aspirin-associated gastric ulcers

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced today top-line results from study 303, a Phase 3 trial designed to track the long-term safety of PA32540 in patients who are at risk for developing aspirin-associated gastric ulcers.

13 Oct 2011

Hydromorphone can be as effective as diacetylmorphine in treating heroin addiction

A clinical trial to test better treatment options for chronic heroin addiction is expected to begin in Vancouver at the end of this year. Led by researchers from Providence Health Care and the University of British Columbia, it's the only clinical trial of its kind in North America.

13 Oct 2011

New insights into how adenovirus triggers an immune response

A Loyola University Chicago Stritch School of Medicine study could lead to improved gene therapies for conditions such as heart disease and cancer as well as more effective vaccines for tuberculosis, malaria and other diseases.

13 Oct 2011

Roundup: N.Y. health insurers seek to keep premium memos secret

Major health insurance companies seeking steep premium increases in New York have submitted memos to state officials to justify the higher rates. Now they are fighting to keep the memos from the public, saying they include trade secrets that competitors could use against them.

13 Oct 2011

Autism Speaks announces 10 new research grants

Autism Speaks, the world's largest autism science and advocacy organization, today announced the awarding of 10 new research grants totaling $1,782,934 in funding over the next three years. The selected studies will evaluate the effectiveness of a broad array of promising behavioral and medical treatments for core symptoms and associated medical issues in children, adolescents, and adults with autism spectrum disorders.

13 Oct 2011

RAZCER (Rapid Astrazeneca and CARO Evaluation of Radio-modifiers) awards announced - five Canadians win

Five leading Canadian radiation oncologists receive RAZCER Awards of $22,727 each for novel studies of radiation-drug interactions that have the potential to either protect normal tissues or sensitize tumours, and thus to enhance the effectiveness of radiation therapy for cancer patients. A selection committee of members of the Canadian Association of Radiation Oncology (CARO) selected the 2011 recipients from among a field of 12 applicants. Astrazeneca provides the funds for the RAZCER Award as an educational grant.

13 Oct 2011

Breast-reconstruction procedure can preserve mammary artery for future cardiac surgery

Doctors at Johns Hopkins have shown that during an increasingly popular type of breast-reconstruction surgery, they can safely preserve the internal mammary artery, in case it is needed for future cardiac surgery.

13 Oct 2011

Skin cell to liver cell shows promise for genetic liver disease

In a new scientific breakthrough, researchers have taken skin cells from a patient with liver disease and turned them into replacement liver cells. Although the procedure is years before it can be used in humans, but if approved, it could launch a new era of personalized therapies for serious genetic disorders.

13 Oct 2011

Children under the age of 3 with NLDO more likely to develop amblyopia

Amblyopia, sometimes referred to as "lazy eye," is a cause of poor vision in children. It occurs in about 1.6% to 3.6% of the general population. Early treatment is critical, as the first few years are the most important in the development of eyesight. If amblyopia is not treated in the first 6 to 10 years, poor vision becomes permanent and cannot be corrected.

13 Oct 2011

Affymetrix launches Axiom Pan-African Array

Affymetrix, Inc. today announced at the ICHG/ASHG annual conference in Montreal, the worldwide launch of the Axiom Genome-Wide Pan-African Array, the first commercial product to maximize genomic coverage of both common and rare alleles in populations of African ancestry, including West African, East African, and African American.

13 Oct 2011

Peanut allergy could be switched off

Now researchers may have discovered how to switch off food allergies. Researchers from Northwestern University found a way to tweak the immune system so that it doesn’t react when foods like peanuts and eggs are encountered – in mice.

12 Oct 2011

Ovarian cancer patients survive longer with BRCA2 mutation in tumors

Among women with a certain type of high-grade ovarian cancer, having BRCA2 genetic mutations, but not BRCA1, was associated with improved overall survival and improved response to chemotherapy, compared to women with BRCA wild-type, according to a study in the October 12 issue of JAMA.

12 Oct 2011

CU Cancer Center test identifies key biomarkers in advanced lung cancer

Researchers at the University of Colorado Cancer Center have developed a test that identifies key biomarkers in advanced lung cancer that helped reduce the risk of death by 36 percent over a 30- month period in a recent clinical trial.

12 Oct 2011

British scientist wins NYSCF - Robertson Stem Cell Prize

The New York Stem Cell Foundation (NYSCF) announced today that a British stem cell scientist working to cure blindness will be the first recipient of The New York Stem Cell Foundation - Robertson Prize in Stem Cell Research, a $200,000 prize awarded annually for extraordinary achievement in translational stem cell research.

12 Oct 2011

AFFiRiS receives MJFF grant for clinical study of AFFITOPE PD01

The Michael J. Fox Foundation (MJFF) today announced that it has awarded $1.5 million to AFFiRiS AG, a Vienna, Austria-based biotech company, for a clinical study of AFFITOPE PD01, a first-of-its-kind Parkinson's disease (PD) vaccine.

12 Oct 2011

NIH, Genesis Biopharma enter Patent License Agreement for adoptive cell therapy

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer immunotherapies, today announced it has entered into a Patent License Agreement with the National Institutes of Health, an agency of the United States Public Health Service within the Department of Health and Human Services

12 Oct 2011

Shield commences two ST10 Phase 3 studies in iron deficiency anaemia

Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease.

12 Oct 2011

UCLA's screening system can target stem cells responsible for glioblastoma

Researchers with UCLA's Jonsson Comprehensive Cancer Center have developed and used a high-throughput molecular screening approach that identifies and characterizes chemical compounds that can target the stem cells that are responsible for creating deadly brain tumors.

12 Oct 2011